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ABSTRACT 
 
Aim: The benefit of statin administration in the secondary prevention of cardiovascular diseases in 
type 2 diabetes mellitus (T2DM) is well documented. The aim of the study was to evaluate the 
characteristics of lipid lowering therapy and the attainment of target values.  
Study Design: Retrospective data analysis. 
Place and Duration of Study: Between 2009 and 2011, Hungary. 
Methodology: The study was conducted on the patients with T2DM and established cardiovascular 
events of general practitioners and specialists from the MULTI GAP (MULTI Goal Attainment 
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Problem) survey in Hungary using standardized, structured questionnaires. Data collection was 
performed in 2009 (1582 patients, 55.0% men), in 2010 (1159 patients, 58.4% men) and in 2011 
(668 patients, 59.1% men).  
Results: In this study all patients received statins, the most frequently used was atorvastatin, 
followed in 2009 by simvastatin and 2011 by rosuvastatin. Fibrates were taken by 9.3–11.3% of 
patients and ezetimibe by 8.0–15.9% of patients. The total cholesterol (TC) values in 2009, in 2010 
and in 2011 were 5.27±1.23 mmol/l, 4.90±1.30 mmol/l, 4.88±1.29 mmol/l, respectively (p>0.05). The 
LDL-cholesterol (LDL-C) values were 2.94±1.04 mmol/l, 2.73±0.95 mmol/l, 2.69±1.03 mmol/l, 
respectively (p>0.05). The proportion of patients at LDL-C target value of <2.5 mmol/l was 35.2%, 
42.8%, 47.8% (p<0.001 vs values in 2009) while that of <1.8 mmol/l was 10.6%, 15.9% and 16.8%, 
respectively (p<0.001 vs values in 2009). There was a linear correlation between the patient 
compliance estimated by the physicians and the LDL-C achievement rate. 
Conclusions: In 2009-2011, a slight improvement in serum cholesterol levels and a significant 
increase of patients at target TC or LDL-C values were documented among patients with T2DM and 
cardiovascular diseases. Nevertheless, the authors find very important to improve the quality of lipid 
lowering treatment in order to increase the number of patients achieving their target lipid values.  
 
 
Keywords: Type 2 diabetes mellitus; cardiovascular risk factor; serum lipids; serum cholesterol; lipid-
lowering treatment; statins. 
 
1. INTRODUCTION 
 
Cardiovascular disease is a chronic macro-
angiopathic complication of type 2 diabetes [1]. 
The mortality statistics derived from several 
cross-sectional studies, follow-up surveys and 
population observation studies of patients with 
type 2 diabetes mellitus (T2DM) have shown that 
cardiovascular conditions, mainly myocardial 
infarction and ischemic stroke, are the leading 
causes of mortality. Lipid disorders play an 
important role in the fact that cardiovascular 
diseases are the most frequent chronic 
complications in T2DM. As a result, the primary 
and secondary prevention of cardiovascular 
events has recently become a significant public 
health challenge in T2DM [2]. 
 
The importance of the secondary prevention of 
cardiovascular diseases in diabetes is supported 
by a serie of studies [2,3,4,5,6,7]. It is well 
documented that in T2DM the occurrence of 
myocardial infarction is more frequent, mortality 
in the acute period is higher, and post-infarction 
late cardiac complications are more common 
than in patients with a healthy glucose 
metabolism. It has been shown that in post-
myocardial infarction diabetic patients, the 
occurrence of congestive heart failure related to 
left ventricle  dysfunction (in severe cases 
cardiogenic shock) and reinfarction rates are 
higher, and the five year survival rate is lower 
than in non-diabetics [2,3,4,6]. 
 
Haffner et al. [8] in their follow-up study 
demonstrated that in post-myocardial infarction 
diabetics the reinfarction rate is approximately 
twice (45%) that of post-MI non-diabetics 
(18.8%) or those diabetics who have not 
previously suffered a heart attack (20.2%). In the 
OASIS multicenter study, patients with non-Q-
myocardial infarction or unstable angina requiring 
hospitalization were followed for up to two years. 
In a randomized sample of 8,013 patients, 1,718 
(21%) suffered from T2DM. In this group the rate 
of deaths within hospital was 2.9% and the 
occurrence of congestive heart failure 12%; in 
non-diabetics the rates were 2% and 8%, 
respectively [9]. In T2DM, apart from coronary 
events, carotid and peripheral arterial disease 
also have major clinical significance as well. It is 
the nature of the disease that if atherosclerosis is 
present in one area, it may be assumed that 
other areas are also involved.  
 
In T2DM the importance of secondary prevention 
of cardiovascular diseases is clear. This consists 
of lifestyle modification and pharmacological 
therapy. In the latter, lipid lowering treatment is of 
increasing importance [2]. This involves the 
lowering of LDL-cholesterol (LDL-C) despite the 
fact that in T2DM the typical dyslipidaemia is an 
increase in triglycerides and rate of small dense 
LDL and a decrease in HDL-cholesterol (HDL-C). 
The drugs of first choice are statins both in non-
diabetics and diabetics. In this study the LDL-C 
and total cholesterol (TC) goals are those 
recommended by the 4th Hungarian Cardio-
vascular Consensus Conference [10]. In high-risk 
patients (such as those with T2DM) the levels 
are 2.5 mmol/l and 4.5 mmol/l, respectively; in 
very high-risk cases (including patients with 
T2DM and coronary artery disease) the levels 
are 1.8 mmol/l and 3.5 mmol/l, respectively [10]. 
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Using data from the diabetic patient subgroup of 
the Hungarian Multi-Goal Attainment Problem 
(MULTI-GAP) 2009, 2010, and 2011 studies 
[11,12,13], this paper aims to analyse the 
characteristics of lipid lowering, the data on the 
trend of LDL-C levels and the attainment of LDL-
C goals.  
 
2. METHODS 
 
In this study, we analysed the Hungarian MULTI-
GAP 2009, 2010, and 2011 survey data collected 
from patients with T2DM, using structured 
questionnaires to monitor the effectiveness of 
lipid lowering therapy among high-risk patients of 
general practitioners (GPs) and specialists. 
Further details on the methods and the results of 
these studies are provided elsewhere 
[10,11,12,13,14]. During the study, the principles 
of the Declaration of Helsinki were observed. The 
research was approved by the Scientific and 
Research Ethics Board of the Hungarian Ministry 
of Health and the patients gave their consent to 
participate. 
 
Risk classification was performed according to 
the recommendations of the 4th Hungarian 
Cardiovascular Consensus Conference: patients 
with T2DM are categorized as high-risk, while 
diabetic patients with a history of acute coronary 
syndrome or other vascular event are 
categorized as very high-risk patients. In the 
MULTI GAP studies each patient has a 
documented history of a cardiovascular event 
and are thus within the very high-risk category 
[10]. 
 
The number of specialists (internists, 
diabetologists, cardiologists, neurologists) 
involved varied between 129 and 149, and that of 
GPs between 53 and 106. The participating 
doctors were asked to collect the data of the last 
10 patients to have suffered from acute coronary 
syndrome, stroke, transient ischaemic attack 
(TIA), and/or peripheral arterial disease.  
 
We registered the patients’ gender, age, 
anthropometric parameters, the presence of 
diabetes and hypertension, smoking habits and 
certain laboratory parameters (HbA1c, fasting and 
postprandial glucose level, lipid levels), and the 
patients were asked about their medical 
cardiovascular prevention treatment. The results 
of this study were obtained in the same way as 
those of all MULTI GAP survey [11,12,13,14]. In 
terms of antidiabetic therapy, the diabetics were 
asked only about the main groups of drugs 
(alpha-glucosidase inhibitors, sulphonylurea 
derivatives, biguanides [metformin], thiazolidine-
diones, insulin, DPP-4-inhibitors). The laboratory 
data were analysed locally in accredited 
laboratories. The patients’ LDL-C, total 
cholesterol, HDL-C, and TG levels were available 
for analysis, the measurements of one patient 
were made in the same local lab. LDL-C values 
were accepted regardless of whether they were 
measured directly or calculated using the 
Friedewald formula [15], except in cases where 
the triglyceride levels were above 4.5 mmol/L 
(400 mg/dL) when only direct measurements 
were accepted. We also analysed the data of 
T2DM patients taking statins: There were 1,582 
in 2009, 1,159 in 2010, and 668 in 2011 (the 
proportion of males was 55.0%, 58.4% and 
59.1%, respectively).  
 
Data collection was also undertaken to examine 
patients’ compliance. As we had no opportunity 
to count the number of tablets taken, this was 
estimated by doctors and was based on the 
frequency of statin prescription, the patients’ 
knowledge and questioning of the patients. The 
analysis of patients’ compliance was undertaken 
by pooling the data for the three years.         
       
2.1 Statistical Analyses 
 
Descriptive statistics are presented as 
frequencies and percentages for categorical 
variables and as the mean values ±SD for 
continuous variables. Categorical variables were 
compared using the chi-square test. The Mann–
Whitney U test was used for continuous 
parametric variables. All tests were two-sided, 
and p values < 0.05 were considered statistically 
significant. Statistical analyses were performed 
using SPSS 7.5. 
 
3. RESULTS 
 
The most important clinical parameters of 
patients across the years 2009, 2010, and     
2011 were: Age (years) 64.1±9.9, 65.4±9.2, 
66.2±9.8; body weight (kg) 87.7±15.7, 87.8±15.7, 
86.6±16.4; Body Mass Index (BMI, kg/m2) 
30.2±5.6, 30.6±5.2, 30.6±5.1.    
 
Across the three years examined, the TC and 
LDL-C values decreased continuously (p > 0.05). 
Although the target values recommended for 
high-risk patients (TC <4.5 mmol/l, LDL-C <2.5 
mmol/l) and for very high-risk patients (TC <3.5 
mmol/l, LDL-C <1.8 mmol/l) were attained to a 
statistically higher degree, these remained lower 
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than 50% concerning the goals for high-risk 
patients and lower than 20% for the very high-
risk cases. (As the 2TDM patients in the MULTI 
GAP studies are in the very high-risk category, 
the unfavourable latter values should mainly be 
taken into account). A greater improvement in 
goal attainment was observed between 2009 and 
2010, than between 2010 and 2011 (Table 1).  
 
The value of HbA1c was 7.29±1.09% in 2009 and 
7.23±1.17% in 2011 (p = 0.024). The distribution 
of the HbA1c values is presented in Fig. 1.  
 
Table 1. Serum total cholesterol and LDL-cholesterol and the attainment of target values in 
patients taking statins with type 2 diabetes mellitus (MULTI GAP 2009, 2010, 2011 studies) 
 
 2009 
(n=1582) 
2010 
(n=1159) 
2011 
(n=668) 
Total cholesterol 
(mmol/l) 
5.27±1.23 4.90±1.30 4.88±1.29 
LDL-cholesterol 
(mmol/l) 
2.94±1.04 2.73±0.95 2.69±1.03 
The attainment rate of total cholesterol 
<4.5 mmol/l (%) 
24.3 38.4* 40.4*† 
The attainment rate of total cholesterol <3.5 mmol/l 
(%)  
6.0 11.5* 12.0* 
The attainment rate of LDL-cholesterol 
<2.5 mmol/l (%)  
35.2 42.8* 47.8*‡ 
The attainment rate of LDL-cholesterol 
<1.8 mmol/l (%)  
10.6 15.9* 16.8* 
*p<0.001 versus value of 2009; †p<0.05  versus value of 2010; ‡p<0.01  versus value of 2010 
 
 
Fig. 1. Distribution of HbA1c values in patients with type 2 diabetes mellitus participating in the 
MULTI GAP study in the years 2009 and 2011 
 
 
Patients’ % 
HbA1C % 
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There was a linear correlation between the 
estimated patients’ compliance, i.e. their 
willingness to cooperate in drug taking, and the 
achievement of 2.5 mmol/l LDL-C target value 
(Fig. 2). 
 
The most frequently used statin in 2009 was 
atorvastatin, followed by simvastatin and 
rosuvastatin (mean daily doses of 33.8 mg, 31.0 
mg and 18.2 mg, respectively). By 2011, a 
remarkable change had occurred: in second 
place after atorvastatin (mean daily dose 32.9 
mg) was rosuvastatin (mean daily dose 19.5 mg), 
followed by simvastatin (mean daily dose 19.8 
mg). Fibrates were taken by 9.3–11.3% of 
patients and ezetimibe by 8.0–15.9% of patients 
(Fig. 3). 
 
 
 
Fig. 2. Correlation between estimated patients’ compliance and goal  
attainment rate (pooled analysis for three years) 
 
 
 
Fig. 3. The distribution of lipid lowering therapy in patients with type 2 diabetes  
mellitus in 2009, 2010, and 2011 
Patients’ % 
adherence 
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4. DISCUSSION 
 
In the prevention of cardiovascular disease in 
patients with T2DM, the attainment of the LDL-C 
target value assessed by guidelines is of very 
great importance. Triglyceride and HDL-C levels 
are also relevant, but their values as treatment 
goals are less significant. Recently, the level of 
non-high-density lipoprotein cholesterol (non-
HDL-C) has been defined as an additional 
treatment target, secondary to LDL-C, especially 
in conditions associated with high triglyceride 
levels such as T2DM. Nevertheless, the use of 
non-HDL-C has not yet become part of routine 
practice [16,17]. 
 
As for the treatment goals, we have taken into 
consideration the recommendations of the        
4th Hungarian Cardiovascular Consensus 
Conference [10], which are similar to and based 
on those of the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP 
III), and the joint recommendations for the 
treatment of dyslipidemias by the European 
Society of Cardiology, the European 
Atherosclerosis Society (ESC/EAS) and the 
International Society of Atherosclerosis 
[18,19,20]. 
 
The priority of statin therapy in T2DM patients is 
indisputable [2,21] As the LDL-C and TC values 
are high in most diabetics, the use of statins is 
indispensable. In T2DM cases, doctors do not 
have to explain why they administer statins, 
rather they should explain why they do not. In 
this study all patients received statins. We 
analysed separately the attainment rate of lipid 
goals for high-risk patients (TC <4.5 mmol/l, LDL-
C <2.5 mmol/l) and for very high-risk patients 
(TC <3.5 mmol/l, LDL-C <1.8 mmol/l). The less 
strict high-risk lipid goals are recommended for 
patients with atherosclerotic disease (coronary, 
carotid or peripheral) or patients with T2DM. In 
this study, all patients were in the very high-     
risk category as, besides having T2DM, an 
atherosclerotic event had also occurred (this was 
an inclusion criterion). Between 2009 and 2011 a 
decreasing tendency could be observed in LDL-
C and TC levels and the rate of patients 
achieving lipid goals increased. However, despite 
the improvement in the quality of the treatment, 
the high-risk lipid goal attainment rate was less 
than 50%, and that of the very high-risk goals 
was critically less than 20%. In contrast, 
glycaemic control was acceptable (mean HbA1c 
values 7.29–7.23%). 
What could be the reason for the only modest 
improvement derived from the statin therapy? 
This is not specific to diabetes but is common in 
other MULTI GAP analyses [11,12,13,14]. In 
most cases three statins were administered, the 
effectiveness of which is supported by a series of 
studies. In the period analysed, use of the     
most potent statin, rosuvastatin, became more 
frequent. In relation to increasing doses, we 
ascertained that only a slight improvement could 
be obtained by this means. It is well known that 
by doubling the statin dose an additional 5–7% 
lowering of LDL-C could be expected [22]. The 
ezetimibe proved to be an efficient drug not only 
n lowering LDL-C but in the reduction of the 
clinical events too [23]. Its more frequent use of 
would be another possible source of further 
improvement [24,25]. 
 
The most important reason for the failure to 
derive better results from treatment could be 
patients’ compliance. Our data suggest that 
greater willingness to cooperate can significantly 
improve the goal attainment rate. Recently we 
have shown that persistence in taking statins in 
Hungarian patients is very poor: At 12 months 
only 26.3% of T2DM patients were taking         
the statins prescribed [26,27]. To improve        
the patients’ persistence have accentuated 
importance.  
 
The clear advantages of statin administration in 
relation to the cardiovascular endpoints and 
mortality are unquestionable. The potential side 
effects are also well known and these include the 
worsening of glycaemic control, an increased 
rate of new onset diabetes [28,29,30,31,32,33]. 
However, we agree with the opinion that overall 
the favourable effects outweigh the harmful 
effects [21,31]. This is the present standpoint of 
the U.S. Food and Drug Administration (FDA) 
[34]. The use of statins in patients with T2DM is a 
crucial aspect of secondary cardiovascular 
disease prevention. We suppose that their 
administration has played an important role in the 
fact that life expectancy in Hungary increased by 
5.33 years from 1993 to 2010, of which 2.39 
years were accounted for by a decrease in 
cardiovascular mortality [35,36] and this occurred 
despite an increase in the prevalence of some 
other cardiovascular risk factors such as obesity 
and T2DM [37,38].  
 
5. CONCLUSION 
 
Administration of statins is the crucial part of lipid 
lowering therapy in patients with T2DM and 
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cardiovascular diseases. Between 2009 and 
2011 a slight improvement in serum cholesterol 
levels and a significant increase of patients at 
target TC or LDL-C values had been detected. 
Statin use shifted towards the most portent 
atorvastatin and rosuvastatin. Despite these 
favourable changes a continuous need remains 
for more effective lipid lowering treatment in 
order to increase the rate of patients with target 
lipid values. 
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